Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
NOTV vs ICLR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
NOTV vs ICLR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $10M | $9.54B |
| Revenue (TTM) | $513M | $8.10B |
| Net Income (TTM) | $-69M | $599M |
| Gross Margin | 20.9% | 26.9% |
| Operating Margin | -6.0% | 12.2% |
| Forward P/E | — | 10.5x |
| Total Debt | $409M | $3.60B |
| Cash & Equiv. | $22M | $539M |
NOTV vs ICLR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Inotiv, Inc. (NOTV) | 100 | 5.5 | -94.5% |
| ICON Public Limited… (ICLR) | 100 | 74.2 | -25.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NOTV vs ICLR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NOTV is the clearest fit if your priority is growth exposure.
- Rev growth 4.5%, EPS growth 49.6%, 3Y rev CAGR -2.2%
- 4.5% revenue growth vs ICLR's 2.0%
ICLR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.60
- 91.0% 10Y total return vs NOTV's -70.6%
- Lower volatility, beta 1.60, Low D/E 37.8%, current ratio 1.26x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.5% revenue growth vs ICLR's 2.0% | |
| Quality / Margins | 7.4% margin vs NOTV's -13.4% | |
| Stability / Safety | Beta 1.60 vs NOTV's 3.47, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -10.0% vs NOTV's -85.4% | |
| Efficiency (ROA) | 3.6% ROA vs NOTV's -8.9%, ROIC 6.5% vs -4.1% |
NOTV vs ICLR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NOTV vs ICLR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ICLR leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ICLR is the larger business by revenue, generating $8.1B annually — 15.8x NOTV's $513M. ICLR is the more profitable business, keeping 7.4% of every revenue dollar as net income compared to NOTV's -13.4%. On growth, NOTV holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $513M | $8.1B |
| EBITDAEarnings before interest/tax | $25M | $1.4B |
| Net IncomeAfter-tax profit | -$69M | $599M |
| Free Cash FlowCash after capex | -$27M | $996M |
| Gross MarginGross profit ÷ Revenue | +20.9% | +26.9% |
| Operating MarginEBIT ÷ Revenue | -6.0% | +12.2% |
| Net MarginNet income ÷ Revenue | -13.4% | +7.4% |
| FCF MarginFCF ÷ Revenue | -5.3% | +12.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.9% | +0.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +65.8% | -98.7% |
Valuation Metrics
NOTV leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, ICLR's 7.9x EV/EBITDA is more attractive than NOTV's 15.9x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $10M | $9.5B |
| Enterprise ValueMkt cap + debt − cash | $397M | $12.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.14x | 13.12x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.53x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.87x |
| EV / EBITDAEnterprise value multiple | 15.88x | 7.95x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 1.15x |
| Price / BookPrice ÷ Book value/share | 0.07x | 1.09x |
| Price / FCFMarket cap ÷ FCF | — | 8.53x |
Profitability & Efficiency
ICLR leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ICLR delivers a 6.3% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-50 for NOTV. ICLR carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to NOTV's 3.01x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs NOTV's 4/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -50.4% | +6.3% |
| ROA (TTM)Return on assets | -8.9% | +3.6% |
| ROICReturn on invested capital | -4.1% | +6.5% |
| ROCEReturn on capital employed | -7.0% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 3.01x | 0.38x |
| Net DebtTotal debt minus cash | $387M | $3.1B |
| Cash & Equiv.Liquid assets | $22M | $539M |
| Total DebtShort + long-term debt | $409M | $3.6B |
| Interest CoverageEBIT ÷ Interest expense | -0.54x | 3.96x |
Total Returns (Dividends Reinvested)
ICLR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ICLR five years ago would be worth $5,463 today (with dividends reinvested), compared to $105 for NOTV. Over the past 12 months, ICLR leads with a -10.0% total return vs NOTV's -85.4%. The 3-year compound annual growth rate (CAGR) favors ICLR at -13.0% vs NOTV's -64.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -45.5% | -33.7% |
| 1-Year ReturnPast 12 months | -85.4% | -10.0% |
| 3-Year ReturnCumulative with dividends | -95.3% | -34.1% |
| 5-Year ReturnCumulative with dividends | -98.9% | -45.4% |
| 10-Year ReturnCumulative with dividends | -70.6% | +91.0% |
| CAGR (3Y)Annualised 3-year return | -64.0% | -13.0% |
Risk & Volatility
ICLR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ICLR is the less volatile stock with a 1.60 beta — it tends to amplify market swings less than NOTV's 3.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICLR currently trades 59.2% from its 52-week high vs NOTV's 8.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.47x | 1.60x |
| 52-Week HighHighest price in past year | $3.32 | $211.00 |
| 52-Week LowLowest price in past year | $0.22 | $66.57 |
| % of 52W HighCurrent price vs 52-week peak | +8.9% | +59.2% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 62.1 |
| Avg Volume (50D)Average daily shares traded | 687K | 1.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $149.63 |
| # AnalystsCovering analysts | — | 30 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.2% |
ICLR leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NOTV leads in 1 (Valuation Metrics).
NOTV vs ICLR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NOTV or ICLR a better buy right now?
For growth investors, Inotiv, Inc.
(NOTV) is the stronger pick with 4. 5% revenue growth year-over-year, versus 2. 0% for ICON Public Limited Company (ICLR). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate ICON Public Limited Company (ICLR) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NOTV or ICLR?
Over the past 5 years, ICON Public Limited Company (ICLR) delivered a total return of -45.
4%, compared to -98. 9% for Inotiv, Inc. (NOTV). Over 10 years, the gap is even starker: ICLR returned +91. 0% versus NOTV's -70. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NOTV or ICLR?
By beta (market sensitivity over 5 years), ICON Public Limited Company (ICLR) is the lower-risk stock at 1.
60β versus Inotiv, Inc. 's 3. 47β — meaning NOTV is approximately 117% more volatile than ICLR relative to the S&P 500. On balance sheet safety, ICON Public Limited Company (ICLR) carries a lower debt/equity ratio of 38% versus 3% for Inotiv, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — NOTV or ICLR?
By revenue growth (latest reported year), Inotiv, Inc.
(NOTV) is pulling ahead at 4. 5% versus 2. 0% for ICON Public Limited Company (ICLR). On earnings-per-share growth, the picture is similar: Inotiv, Inc. grew EPS 49. 6% year-over-year, compared to 28. 8% for ICON Public Limited Company. Over a 3-year CAGR, ICLR leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NOTV or ICLR?
ICON Public Limited Company (ICLR) is the more profitable company, earning 9.
6% net margin versus -13. 4% for Inotiv, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICLR leads at 13. 3% versus -6. 0% for NOTV. At the gross margin level — before operating expenses — ICLR leads at 29. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NOTV or ICLR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NOTV or ICLR better for a retirement portfolio?
For long-horizon retirement investors, ICON Public Limited Company (ICLR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Inotiv, Inc. (NOTV) carries a higher beta of 3. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ICLR: +91. 0%, NOTV: -70. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NOTV and ICLR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NOTV is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.